Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00697151 · ClinicalTrials.gov registry record · Phase 4

Patent Foramen Ovale in Cryptogenic Stroke Study

A Phase 4 study of Ischemic Stroke and Patent Foramen Ovale, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
630
Enrollment target
1
Study location

NCT00697151: Completed Phase 4 study of Ischemic Stroke and Patent Foramen Ovale, sponsored by Columbia University.

NCT00697151 is a Phase 4 study of Ischemic Stroke and Patent Foramen Ovale that has completed, run by Columbia University. The registered enrollment target is 630 participants, below the 1,454-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00697151, a Phase 4 study of Ischemic Stroke and Patent Foramen Ovale, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
630 participants
Enrollment target
1
Study location

Study Summary

The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.

Interventions

  • DRUG Aspirin
  • DRUG Warfarin

Study Locations (1)

New York

  • Columbia College of Physicians and Surgeons - New York

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 1993-06
Est. Completion 2000-06
Phase Phase 4
Columbia University

958 total trials

What the finished NCT00697151 record still lists

NCT00697151 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, below the 1,454-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (57% lower).

The record links to 2 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.

NCT00697151 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00697151 about?

NCT00697151 is a clinical study titled "Patent Foramen Ovale in Cryptogenic Stroke Study". The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.

What is the current status of trial NCT00697151?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 630 participants. The study started on 1993-06. Estimated completion is 2000-06.

What conditions does trial NCT00697151 study?

This clinical trial studies the following conditions: Ischemic Stroke, Patent Foramen Ovale.

What interventions are being tested in trial NCT00697151?

The interventions under investigation include: Aspirin (DRUG), Warfarin (DRUG).

Who is sponsoring clinical trial NCT00697151?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00697151 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00697151's enrollment target sits among peer trials

630 13th of 66 higher than 54 of 66 other Ischemic Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04704921 · 630 participants · Phase 2

    Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

  • NCT04707729 · 630 participants · NA

    ROX Index for the Timing of Intubation in Nasal High Flow

  • NCT05061550 · 630 participants · Phase 2

    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • NCT05224440 · 630 participants · NA

    National Sponsorship Program for Transitioning Service Members

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00697151, the US trial registry maintained by the National Library of Medicine. NCT00697151 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.